China Peptide Therapeutics Market Trends, Research Report, Growth, Opportunities, Forecast 2021-2027

China's peptide therapeutics market will see a considerable growth of 6.8% during the forecast period. Since the last decade, China has emerged as a globally preferred destination for the outsourcing of drug research. The robust growth of China’s Contract Research (CRO) industry is encouraging the transition of outsourcing services at a large scale, thereby contributing to drug innovation. A significant portion of the research is being outsourced each year by the global innovator companies as part of R&D restructuring and cost-cutting initiative, especially in the analytical chemistry and peptide services.

A full report of China Peptide Therapeutics Market is available at: https://www.omrglobal.com/industry-reports/china-peptide-therapeutics-market-share

China has many domestic players offering outsourcing services to global companies in the peptide area. For instance, the Chinese Peptide Company (CPC) offers services to AstraZeneca Plc, Pfizer Inc., among other companies, around custom synthetic peptide, or API manufacturing. In addition, the companies across the country are partnering and collaborating with various global players to expand the peptide therapeutics market offerings.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/china-peptide-therapeutics-market

For instance, in January 2016, ChemPartner expanded its CRO service offerings into peptide chemistry with a significant investment in personnel and infrastructure, including the acquisitions of parallel peptide synthesis equipment. The initiative will enable the company to partner with other companies in therapeutic peptide drug discovery and partnership in other functional areas including biology, pharmacology, and Drug Metabolism and Pharmacokinetics (DMPK).

Market Coverage

• Study Period- 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segments Covered- By Route of Administration and By Application
• Key Companies Profiled- Eli Lilly & Co., Amgen Inc., AstraZeneca Plc, Astellas Inc., Pfizer Inc., and Teva Pharmaceuticals Co. Ltd.

Key questions addressed by the report

• What is the market growth rate during the forecast period?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market during the forecast period?
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

China Peptide Therapeutics Market – Segmentation

By Route of Administration

• Oral
• Parenteral

By Application

• Cancer
• Metabolic Disorder
• Gastrointestinal Disorders
• Central Nervous System Disorders
• Respiratory Disorders
• Others (Kidney Disorder and Autoimmune Disorder)

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/china-peptide-therapeutics-market-share

Company Profiles

• Amgen, Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Eli Lilly and Co.
• GlaxoSmithKline PLC
• Novartis International AG
• Pfizer Inc.
• Simcere Pharmaceutical Group
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Qingdao Primedicine Pharmaceutical Co. Ltd.

Reasons to Buying From us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.